Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 11/20 | 0.75 |
| ▸ | GPR34 | Q9UPC5 | 7/20 | 0.75 |
| ▸ | GPR174 | Q9BXC1 | 7/20 | 0.75 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.71 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.71 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | FABP3 | P05413 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22532171 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL21795574 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22533153 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| Phosphatidyl Serine SCHEMBL20767229 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22498713 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22531350 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| Phosphatidyl Serine SCHEMBL24802704 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22532168 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22531357 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22532089 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 760 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734964-A1 | LIPID PARTICLES FOR DELIVERING A PAYLOAD | Repertoire Immune Medicines, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| US-20260054227-A1 | COMPOSITE MEMBRANE AND METHOD OF MAKING THE SAME | H2MO TECH PTE LTD (SG) | 2026-02-26 | — | — | US | claimed |
| US-12485388-B2 | Composite membrane and method of making the same | H2MO TECHNOLOGY PTE LTD (SG) | 2025-12-02 | — | — | US | claimed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | claimed |
| EP-4610652-A1 | YAXAB NANOPORE, NANOPORE SYSTEM COMPRISING SAME AND APPLICATIONS THEREOF | Korea Research Institute of Bioscience and Biotechnology (KR) | 2025-09-03 | — | — | EP | claimed |
| CN-120051687-A | YaxAB nanopores, nanopore systems comprising the YaxAB nanopores and uses thereof | 韩国生命工学研究院 | 2025-05-27 | — | — | CN | claimed |
| WO-2025083024-A1 | IMPROVED FORMULATIONS OF AUTOANTIGEN CONJUGATES | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2025-04-24 | — | — | WO | claimed |
| WO-2025075976-A2 | METHYL-BRANCHED LIPOSOMES FOR SUSTAINED DRUG DELIVERY | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-04-10 | — | — | WO | claimed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| US-12226740-B2 | Stabilized filtration device | RETEIN AB (SE) | 2025-02-18 | — | — | US | claimed |
| WO-2009129395-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | claimed |
| US-20080160313-A1 | Lipid bilayers on nanotextured solid surfaces | ENERGY, U.S. DEPARTMENT OF | 2008-07-03 | — | — | US | claimed |
| US-20080154101-A1 | Implantable Biosensor and Methods of Use Thereof | THE UNIVERSITY OF CONNECTICUT | 2008-06-26 | — | — | US | claimed |
| EP-1855595-A2 | PHARMACEUTICAL LIPOSOMAL COMPOSITIONS | ID Biomedical Corporation of Quebec c.o.b. as Glaxosmithkline Biologicals North America (CA) | 2007-11-21 | — | — | EP | claimed |
| US-20070014841-A1 | Pharmaceutical compositions | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2007-01-18 | — | — | US | claimed |
| US-20070014842-A1 | Pharmaceutical liposomal compositions | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2007-01-18 | — | — | US | claimed |
| WO-2006096701-A2 | PHARMACEUTICAL LIPOSOMAL COMPOSITIONS | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2006-09-14 | — | — | WO | claimed |
| EP-1536831-A2 | PHARMACEUTICAL LIPOSOMAL COMPOSITIONS CONTAINING N. MENINGITIDIS DERIVED POLYPEPTIDES OR POLYNUCLEOTIDES | ID Biomedical Corporation (CA) | 2005-06-08 | — | — | EP | claimed |
| US-20040132652-A1 | Pharmaceutical compositions | SHIRE BIOCHEM INC. (CA) | 2004-07-08 | — | — | US | claimed |
| WO-2004019976-A2 | PHARMACEUTICAL LIPOSOMAL COMPOSITIONS CONTAINING N. MENINGITIDIS DERIVED POLYPEPTIDES OR POLYNUCLEOTIDES | ID BIOMEDICAL CORPORATION (CA) | 2004-03-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | P2RY10 1962/4885GPR34 2267/4885GPR174 1670/4885 |
| US-20260054227-A1 | COMPOSITE MEMBRANE AND METHOD OF MAKING THE SAME | AQP1, AQP4, AQP3 | P2RY10 376/4885GPR34 4314/4885GPR174 4645/4885 |
| US-20070014842-A1 | Pharmaceutical liposomal compositions | NGLY1, PHOSPHO1, LPXN | P2RY10 1599/4885GPR34 2532/4885GPR174 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.